NF1 Root Cause Therapy
Neurofibromatosis Type 1 (NF1)
Pre-clinicalActive
Key Facts
About Infixion Bioscience
Infixion Bioscience is a private, pre-clinical biotech founded in 2021, focusing exclusively on Neurofibromatosis Type 1 (NF1). The company is developing a novel therapeutic approach designed to restore functional neurofibromin protein, targeting the genetic root cause of the disease rather than just symptoms. Operating in the rare disease space with significant market incentives, Infixion appears to be in the early stages of research and development, supported by foundational grants and engagement with the NF community. Its success hinges on validating its unique mechanism and advancing a candidate into clinical trials.
View full company profileTherapeutic Areas
Other Neurofibromatosis Type 1 (NF1) Drugs
| Drug | Company | Phase |
|---|---|---|
| PAS-004 (MEK Inhibitor) | Pasithea Therapeutics | Preclinical |